<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Ther</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Ther</journal-id><journal-id journal-id-type="pmc-domain-id">2527</journal-id><journal-id journal-id-type="pmc-domain">infecdisther</journal-id><journal-title-group><journal-title>Infectious Diseases and Therapy</journal-title></journal-title-group><issn pub-type="ppub">2193-8229</issn><issn pub-type="epub">2193-6382</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10390440</article-id><article-id pub-id-type="pmcid-ver">PMC10390440.1</article-id><article-id pub-id-type="pmcaid">10390440</article-id><article-id pub-id-type="pmcaiid">10390440</article-id><article-id pub-id-type="pmid">37329414</article-id><article-id pub-id-type="doi">10.1007/s40121-023-00823-z</article-id><article-id pub-id-type="publisher-id">823</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Na&#239;ve, Compensated Cirrhotic HCV Patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Reau</surname><given-names initials="N">Nancy</given-names></name><address><email>Nancy_Reau@rush.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheng</surname><given-names initials="WH">Wei-Han</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shao</surname><given-names initials="Q">Qiujun</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marx</surname><given-names initials="SE">Steven E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brooks</surname><given-names initials="H">Hannah</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martinez</surname><given-names initials="A">Anthony</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.240684.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0705 3621</institution-id><institution>Rush University Medical Center, </institution></institution-wrap>1725 W. Harrison St., Suite 158, Chicago, IL 60612 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.431072.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 4227</institution-id><institution>AbbVie Inc., </institution></institution-wrap>North Chicago, IL USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.273335.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9887</institution-id><institution>Jacobs School of Medicine and Biomedical Sciences, </institution><institution>University at Buffalo, State University of New York, </institution></institution-wrap>Buffalo, NY USA </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2023</year></pub-date><volume>12</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">442030</issue-id><fpage>1849</fpage><lpage>1860</lpage><history><date date-type="received"><day>20</day><month>9</month><year>2021</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>06</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>02</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-08-02 02:25:09.887"><day>02</day><month>08</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40121_2023_Article_823.pdf"/><abstract id="Abs1"><sec><title>Introduction</title><p id="Par1">The EXPEDITION-8 clinical trial has demonstrated that treatment-na&#239;ve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1&#8211;6 can achieve a 98% intent-to-treat sustained virologic response rate 12&#160;weeks post-treatment with an 8-week glecaprevir/pibrentasvir (G/P) regimen. Further real-world evidence is needed to support the effectiveness of 8-week G/P in a clinical practice setting and to consolidate these treatment recommendations. The aim of this study is to contribute real-world evidence for the effectiveness of an 8-week G/P treatment in TN/CC patients with HCV genotypes 1&#8211;6.</p></sec><sec><title>Methods</title><p id="Par2">Retrospective real-world data from 494 TN/CC patients with HCV genotypes 1&#8211;6 were collected between August 2017 to December 2020 from the Symphony Health Solutions administrative claims database. Demographic and clinical characteristics were collected at baseline. Patients were required to have a follow-up HCV ribonucleic acid level at least 8&#160;weeks or more after the end of treatment. The percentage of patients achieving a sustained virologic response (SVR) is reported.</p></sec><sec><title>Results</title><p id="Par3">The majority of patients were male (58%) and Caucasian (40%), with a mean age of 58&#160;years; 74%, 12%, 12%, and 1% of patients were HCV genotype 1, 2, 3, and 4&#8211;6 infected, respectively. SVR was achieved in 95.5% of all patients. Across patient subgroups, SVR was achieved in 95.6% of patients with HCV genotype 3 and in 93% of HCV patients with a recent diagnosis of illicit drug use or abuse (within 6&#160;months prior to G/P initiation).</p></sec><sec><title>Conclusion</title><p id="Par4">Early real-world evidence indicates high effectiveness of the 8-week G/P regimen in TN/CC patients of HCV genotypes 1&#8211;6 from a large US claims database.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40121-023-00823-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Compensated cirrhosis</kwd><kwd>Glecaprevir</kwd><kwd>Pibrentasvir</kwd><kwd>Hepatitis C virus</kwd><kwd>Infectious diseases</kwd><kwd>Treatment na&#239;ve</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006483</institution-id><institution>AbbVie</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Healthcare Ltd., part of Springer Nature 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d32e318"><title>Key Summary Points</title><p id="Par05">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">Why carry out this study?</italic></bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">The EXPEDITION-8 clinical trial has demonstrated that treatment-na&#239;ve patients with compensated cirrhosis (TN/CC) of HCV genotypes 1&#8211;6 achieve a 98% intent-to-treat sustained virologic response rate 12&#160;weeks post-treatment with an 8-week glecaprevir/pibrentasvir (G/P) regimen, including HCV genotype 3 and patients with a recent diagnosis of illicit drug use or abuse</td></tr><tr><td align="left" colspan="1" rowspan="1">This study presents real-world evidence for the effectiveness of 8-week G/P in TN/CC patients with HCV</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold><italic toggle="yes">What was learned from the study?</italic></bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Overall, 8-week G/P treatment in TN/CC HCV patients was highly effective, with an overall cure rate of 95.5%, including in patients with genotype 3 (95.6%) and patients with a recent diagnosis of illicit drug use or abuse (93%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Results from this real-world analysis provide further evidence for the 8-week G/P regimen as an efficacious and short-duration treatment in TN/CC patients with all HCV genotypes in this real-world setting</td></tr><tr><td align="left" colspan="1" rowspan="1">This study redefines the historical length of treatment for TN/CC HCV patients, supporting efforts towards the World Health Organization&#8217;s goal of eliminating HCV as a major public health threat by 2030</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec2"><title>Introduction</title><p id="Par12">Globally, an estimated 71 million people have chronic hepatitis C virus (HCV) infection [<xref ref-type="bibr" rid="CR1">1</xref>]. In the United States (US), it was estimated that 2.4 million people had active HCV between 2013 and 2016 [<xref ref-type="bibr" rid="CR2">2</xref>]. In 2018, an estimated 50,300 new acute and 137,713 new chronic cases of HCV were identified in a noninstitutionalized civilian population in the US [<xref ref-type="bibr" rid="CR3">3</xref>]. Chronic HCV is associated with progressive liver disease [<xref ref-type="bibr" rid="CR4">4</xref>], extrahepatic manifestations [<xref ref-type="bibr" rid="CR5">5</xref>], and an increase in all-cause mortality [<xref ref-type="bibr" rid="CR6">6</xref>]. The introduction of oral, pangenotypic, ribavirin-free, direct-acting antiviral (DAAs) drugs has improved the efficacy and safety of HCV treatment. DAAs are generally well tolerated and are associated with high cure rates [<xref ref-type="bibr" rid="CR7">7</xref>]. Specifically, glecaprevir/pibrentasvir (G/P) has been approved for the treatment of patients with chronic HCV without cirrhosis or with compensated cirrhosis (CC) [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], where up to 98% of patients can achieve a sustained virologic response at post-treatment week 12 (SVR12) by G/P treatment in only 8&#160;weeks [<xref ref-type="bibr" rid="CR10">10</xref>]. By curing HCV infection, health-related quality of life can be improved, and extrahepatic manifestations [<xref ref-type="bibr" rid="CR11">11</xref>] and onward transmission can be prevented [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par13">Previously, only treatment-na&#239;ve (TN) patients without cirrhosis and with HCV genotypes 1&#8211;6 were eligible for an 8-week regimen of G/P [<xref ref-type="bibr" rid="CR12">12</xref>]. The results of the EXPEDITION-8 trial [<xref ref-type="bibr" rid="CR10">10</xref>] demonstrated the efficacy and safety of 8-week G/P in TN patients with HCV genotypes 1&#8211;6 and CC, including those with genotype 3, leading to approval and label updates for an 8-week treatment duration in these patients in September 2019 in the US [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] and March 2020 in the EU [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. HCV genotype 3 is more difficult to treat and has been associated with significantly lower SVR rates than other genotypes [<xref ref-type="bibr" rid="CR17">17</xref>]. Prior to the EXPEDITION-8 trial outcomes, a highly effective 12-week regimen of G/P for TN/CC patients with genotype 3 yielded high rates of SVR [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Both the American Association of the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) guidelines previously recommended a 12-week regimen of G/P for TN/CC patients with genotype 3; currently, AASLD recommends 8&#160;weeks of G/P treatment for TN/CC patients with genotype 3, and EASL recommends 8 to 12&#160;weeks of treatment for these patients [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, the new guidelines and label update for a shorter-duration treatment are especially promising for patients infected with more difficult-to-treat HCV infections, such as genotype 3, and for populations that are more difficult to engage and retain in therapy, such as people who inject drugs (PWID) [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par14">Evidence from clinical trials demonstrates that TN/CC patients with genotypes 1&#8211;6 who received treatment for G/P for 8&#160;weeks achieved high rates of SVR12 [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. However, the most-recently published EASL guidelines state that real-world data are needed to consolidate the shortened treatment recommendation of an 8-week regimen [<xref ref-type="bibr" rid="CR8">8</xref>]. Real-world effectiveness data are promising [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], but data from the US are limited. The first real-world evidence from the US demonstrated a high SVR12 rate (&#8805;&#8201;95%) following an 8-week regimen of G/P for TN/CC patients with genotype 1&#8211;6 chronic HCV infection [<xref ref-type="bibr" rid="CR26">26</xref>]. The aim of this study is to assess the real-world effectiveness of 8-week G/P in TN/CC patients with chronic HCV infection using information from a large US claims database.</p></sec><sec id="Sec3"><title>Methods</title><sec id="Sec4"><title>Study Design and Data Source</title><p id="Par15">This was a retrospective, real-world study that examined SVR12 rates among TN/CC patients with HCV in the US who were treated with 8-week G/P. Real-world, anonymized data from across the US between August 2017 and December 2020 were collated from the Symphony Health Solutions (SHS) administrative claims database, a large and geographically diverse set of commercial and government (Medicare and Medicaid) electronic claims processors. Anonymized data were linked to patient-level laboratory results from laboratory testing companies in the US.</p></sec><sec id="Sec5"><title>Patients</title><p id="Par16">Patients were included in the study if they were over the age of 12, had a diagnosis of chronic HCV within 6 months prior to the initial G/P prescription dispensed, and received a diagnosis of cirrhosis (see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Patients were treated with 8-week G/P, defined as a G/P prescription filled for a total days-of-supply of 56&#160;days, with no more than a 7-day gap between fills allowed. A previous publication found that patients with a gap of less than 7&#160;days between fills of G/P can still achieve SVR [<xref ref-type="bibr" rid="CR27">27</xref>].<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Sample identification of eligible patients.<italic toggle="yes"> G/P</italic> glecaprevir/pibrentasvir,<italic toggle="yes"> HCV</italic> hepatitis C virus,<italic toggle="yes"> RNA</italic> ribonucleic acid,<italic toggle="yes"> SHA</italic> Symphony Health Solutions</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40121_2023_823_Fig1_HTML.jpg"/></fig></p><p id="Par17">For all patients, G/P was prescribed to be taken orally, once daily, at a fixed dose of 300&#160;mg/120&#160;mg, for 8&#160;weeks [<xref ref-type="bibr" rid="CR15">15</xref>]. Given that SHS is an open-system claims database, patients were required to have medical or pharmacy claims recorded in the 6&#160;months before the first G/P fill date (as a pre-index proxy for 6 months enrollment), where the index date is defined as the date for the first fill of 8-week G/P. Additionally, patients were required to have a claim recorded any time post the 6-month baseline period as a proxy for continuous enrollment.</p><p id="Par18">Patients were excluded if they received HCV treatment any time before their G/P initiation, had decompensated cirrhosis (excluding those with a prior history of codes associated with hepatic decompensation or hepatic failure any time before their index date; see Table S1 in the Supplementary Information), or had a liver or kidney transplant (excluding those with a prior history of codes for liver or kidney failure any time before their index date; see Table S2 in the Supplementary Information). Patients were required to have a follow-up HCV ribonucleic acid (RNA) level at least 8&#160;weeks or more after the end of treatment. Inconclusive results were excluded.</p></sec><sec id="Sec6"><title>Data Collection</title><p id="Par19">Demographic and clinical characteristics were collected at baseline, including age, gender, payer type, ethnicity, geographic location, and comorbidities (liver-related diseases, HBV infection, extrahepatic manifestations [see Table S3 in the Supplementary Information], illicit drug use [see Table S4 in the Supplementary Information], and portal hypertension). Laboratory values were also collected at baseline, and included HCV genotype, alanine aminotransferase, HCV RNA viral load, platelet, serum albumin, total bilirubin, and ICD-10 for cirrhosis.</p></sec><sec id="Sec7"><title>Outcome</title><p id="Par20">The primary outcome in this study is the SVR rate, calculated in patients who have an HCV RNA level observed at least 8&#160;weeks after the end of G/P treatment. Where the HCV RNA value is undetectable or unquantifiable, it means that SVR was achieved, while a quantifiable HCV RNA means that SVR was not achieved.</p></sec><sec id="Sec8"><title>Statistical Analysis</title><p id="Par21">Descriptive statistics were performed to assess patient characteristics at baseline. The number and percentage of eligible patients with each baseline clinical characteristic and the number and percentage of patients with a diagnosis of a disease among the comorbidities was calculated. The percentage of patients who achieved SVR was calculated among all patients who had an HCV RNA value at least 8&#160;weeks after the end of treatment. Subgroup analyses were explored to repeat the SVR rates based on individual patient&#8217;s baseline viral load, HCV genotype, and comorbidities. Univariate comparisons of patient characteristics between patients who achieved SVR and patients who failed to achieve SVR were made using<italic toggle="yes"> t</italic>-tests for continuous variables and chi-square tests for categorical variables. All statistical tests were two-sided and <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 was considered to be statistically significant. Statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc.).</p></sec><sec id="Sec9"><title>Ethics</title><p id="Par22">Data provided for the study were de-identified and Health Insurance Portability and Accountability Act (HIPAA) compliant; therefore, review board approval was not required.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Patient Attrition</title><p id="Par23">The overall sample size was 123,942 patients treated with G/P (see Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Of these, 4139 patients were HCV treatment-na&#239;ve, had compensated cirrhosis, and did not receive a liver or kidney transplant. Of these, 494 patients met the inclusion and exclusion criteria and had a follow-up HCV RNA level assessed at least 8 weeks or more after the end of treatment, of whom 45 patients were identified as genotype 3.</p></sec><sec id="Sec12"><title>Patient Characteristics</title><p id="Par24">The majority (58%) of the 494 HCV patients included in this analysis were male, Caucasian (40%), and had a mean age of 58&#160;years (see Table <xref rid="Tab1" ref-type="table">1</xref>). Overall, 74%, 12%, 12%, and 1% of the patients were genotype 1, 2, 3, and 4&#8211;6 infected, respectively. Of the 494 patients, 24% had a recent diagnosis of illicit drug use or abuse and 39% had one or more extrahepatic manifestations, which are the diseases defined in Table S3 in the Supplementary Information. The mean HCV RNA viral load for the total population at baseline was 4,634,921&#160;IU/mL, and the mean platelet count was 218.6&#8201;&#215;&#8201;10<sup>9</sup>/L (see Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographics and clinical characteristics of patients who achieved SVR and patients who failed to achieve SVR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Demographics and clinical characteristics</th><th align="left" colspan="1" rowspan="1">Total (<italic toggle="yes">N</italic>&#8201;=&#8201;494)</th><th align="left" colspan="1" rowspan="1">SVR12 achieved (<italic toggle="yes">N</italic>&#8201;=&#8201;472)</th><th align="left" colspan="1" rowspan="1">Failed to achieve SVR (<italic toggle="yes">N</italic>&#8201;=&#8201;22)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age in years</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">55.6&#8201;&#177;&#8201;11.1</td><td align="left" colspan="1" rowspan="1">55.6&#8201;&#177;&#8201;11.1</td><td align="left" colspan="1" rowspan="1">56.0&#8201;&#177;&#8201;11.6</td><td align="left" colspan="1" rowspan="1">0.870</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (min&#8211;max)</td><td align="left" colspan="1" rowspan="1">58 (22&#8211;76)</td><td align="left" colspan="1" rowspan="1">58 (22&#8211;76)</td><td align="left" colspan="1" rowspan="1">59 (33&#8211;70)</td><td align="left" colspan="1" rowspan="1">0.636</td></tr><tr><td align="left" colspan="1" rowspan="1">Group,<italic toggle="yes"> N</italic> (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" rowspan="6" colspan="1">0.748</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;12&#8211;17</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;18&#8211;29</td><td align="left" colspan="1" rowspan="1">12 (2.4)</td><td align="left" colspan="1" rowspan="1">12 (2.6)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;30&#8211;52</td><td align="left" colspan="1" rowspan="1">142 (28.8)</td><td align="left" colspan="1" rowspan="1">136 (28.8)</td><td align="left" colspan="1" rowspan="1">6 (27.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;52&#8211;73</td><td align="left" colspan="1" rowspan="1">329 (66.6)</td><td align="left" colspan="1" rowspan="1">313 (66.3)</td><td align="left" colspan="1" rowspan="1">16 (72.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8201;&#160;&gt;&#8201;73</td><td align="left" colspan="1" rowspan="1">11 (2.2)</td><td align="left" colspan="1" rowspan="1">11 (2.3)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender,<italic toggle="yes"> N</italic> (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" rowspan="3" colspan="1">0.211</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">206 (41.7)</td><td align="left" colspan="1" rowspan="1">194 (41.1)</td><td align="left" colspan="1" rowspan="1">12 (54.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">288 (58.3)</td><td align="left" colspan="1" rowspan="1">278 (58.9)</td><td align="left" colspan="1" rowspan="1">10 (45.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Race/ethnicity,<italic toggle="yes"> N</italic> (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Caucasian</td><td align="left" colspan="1" rowspan="1">194 (39.5)</td><td align="left" colspan="1" rowspan="1">184 (39.2)</td><td align="left" colspan="1" rowspan="1">10 (45.4)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;African American</td><td align="left" colspan="1" rowspan="1">83 (16.9)</td><td align="left" colspan="1" rowspan="1">79 (16.8)</td><td align="left" colspan="1" rowspan="1">4 (18.2)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Hispanic</td><td align="left" colspan="1" rowspan="1">42 (8.6)</td><td align="left" colspan="1" rowspan="1">41 (8.8)</td><td align="left" colspan="1" rowspan="1">1 (4.6)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Other</td><td align="left" colspan="1" rowspan="1">6 (1.2)</td><td align="left" colspan="1" rowspan="1">6 (1.3)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unknown</td><td align="left" colspan="1" rowspan="1">166 (22.8)</td><td align="left" colspan="1" rowspan="1">159 (33.9)</td><td align="left" colspan="1" rowspan="1">7 (31.8)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Region,<italic toggle="yes"> N</italic> (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" rowspan="5" colspan="1">0.110</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Northeast</td><td align="left" colspan="1" rowspan="1">166</td><td align="left" colspan="1" rowspan="1">154 (32.8)</td><td align="left" colspan="1" rowspan="1">12 (54.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Midwest</td><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">44 (9.4)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;West</td><td align="left" colspan="1" rowspan="1">118</td><td align="left" colspan="1" rowspan="1">115 (24.5)</td><td align="left" colspan="1" rowspan="1">3 (13.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;South</td><td align="left" colspan="1" rowspan="1">163</td><td align="left" colspan="1" rowspan="1">156 (33.3)</td><td align="left" colspan="1" rowspan="1">7 (31.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Comorbidities,<italic toggle="yes"> N</italic> (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Illicit drug use</td><td align="left" colspan="1" rowspan="1">115 (23.5)</td><td align="left" colspan="1" rowspan="1">107 (22.7)</td><td align="left" colspan="1" rowspan="1">8 (36.4)</td><td align="left" colspan="1" rowspan="1">0.137</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Extrahepatic manifestation</td><td align="left" colspan="1" rowspan="1">190 (38.5)</td><td align="left" colspan="1" rowspan="1">179 (37.9)</td><td align="left" colspan="1" rowspan="1">11 (50.0)</td><td align="left" colspan="1" rowspan="1">0.255</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SD</italic> standard deviation,<italic toggle="yes"> SVR12</italic> sustained virologic response at post-treatment week 12. Percentages were calculated based on the available data</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Baseline lab values of patients who achieved SVR and patients who failed to achieve SVR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Patient baseline lab values</th><th align="left" colspan="1" rowspan="1">Total (<italic toggle="yes">N&#8201;</italic>=&#8201;494)</th><th align="left" colspan="1" rowspan="1">SVR12 achieved (<italic toggle="yes">N</italic>&#8201;=&#8201;472)</th><th align="left" colspan="1" rowspan="1">Failed to achieve SVR12 (<italic toggle="yes">N</italic>&#8201;=&#8201;22)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Genotype,<italic toggle="yes"> N</italic> (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" rowspan="5" colspan="1">0.905</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;1</td><td align="left" colspan="1" rowspan="1">276 (74.4)</td><td align="left" colspan="1" rowspan="1">264 (71.2)</td><td align="left" colspan="1" rowspan="1">12 (80.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;2</td><td align="left" colspan="1" rowspan="1">44 (11.9)</td><td align="left" colspan="1" rowspan="1">43 (12.1)</td><td align="left" colspan="1" rowspan="1">1 (6.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;3</td><td align="left" colspan="1" rowspan="1">45 (12.1)</td><td align="left" colspan="1" rowspan="1">43 (12.1)</td><td align="left" colspan="1" rowspan="1">2 (13.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;4&#8211;6</td><td align="left" colspan="1" rowspan="1">3 (0.8)</td><td align="left" colspan="1" rowspan="1">3 (0.8)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Alanine aminotransferase,<italic toggle="yes"> N</italic> (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" rowspan="6" colspan="1">0.813</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804; 40&#160;IU/L</td><td align="left" colspan="1" rowspan="1">339 (69.0)</td><td align="left" colspan="1" rowspan="1">325 (69.3)</td><td align="left" colspan="1" rowspan="1">14 (63.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Grade 1 (40&#8211;120&#160;IU/L)</td><td align="left" colspan="1" rowspan="1">123 (25.1)</td><td align="left" colspan="1" rowspan="1">116 (24.7)</td><td align="left" colspan="1" rowspan="1">7 (31.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Grade 2 (121&#8211;200&#160;IU/L)</td><td align="left" colspan="1" rowspan="1">20 (4.1)</td><td align="left" colspan="1" rowspan="1">19 (4.1)</td><td align="left" colspan="1" rowspan="1">1 (4.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Grade 3 (200&#8211;800&#160;IU/L)</td><td align="left" colspan="1" rowspan="1">9 (1.8)</td><td align="left" colspan="1" rowspan="1">9 (1.9)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Grade 4 (&gt;&#8201;800&#160;IU/L)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0 (0)</td><td align="left" colspan="1" rowspan="1">0 (0)</td></tr><tr><td align="left" colspan="1" rowspan="1">RNA viral load (IU/mL)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" rowspan="3" colspan="1">0.645</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">4,634,921&#8201;&#177;&#8201;6,387,884</td><td align="left" colspan="1" rowspan="1">4,660,909&#8201;&#177;&#8201;6,344,355</td><td align="left" colspan="1" rowspan="1">3,949,237&#8201;&#177;&#8201;7,711,806</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (min&#8211;max),<italic toggle="yes"> N</italic></td><td align="left" colspan="1" rowspan="1">2,120,000 (300&#8211;38,900,000)</td><td align="left" colspan="1" rowspan="1">2,138,060 (300&#8211;38,900,000), 347</td><td align="left" colspan="1" rowspan="1">1,800,640 (710&#8211;29,003,000), 13</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelet count (&#215;&#8201;10<sup>9</sup>/L)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">218.6&#8201;&#177;&#8201;76.4</td><td align="left" colspan="1" rowspan="1">218.5&#8201;&#177;&#8201;76.0</td><td align="left" colspan="1" rowspan="1">220.3&#8201;&#177;&#8201;86.9</td><td align="left" colspan="1" rowspan="1">0.863</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (min&#8211;max)</td><td align="left" colspan="1" rowspan="1">212.0 (48.0&#8211;483.0)</td><td align="left" colspan="1" rowspan="1">212.0 (48.0&#8211;483.0)</td><td align="left" colspan="1" rowspan="1">203.5 (78.0&#8211;415.0)</td><td align="left" colspan="1" rowspan="1">0.918</td></tr><tr><td align="left" colspan="1" rowspan="1">Albumin (g/dL)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">4.2&#8201;&#177;&#8201;0.5</td><td align="left" colspan="1" rowspan="1">4.2&#8201;&#177;&#8201;0.5</td><td align="left" colspan="1" rowspan="1">4.1&#8201;&#177;&#8201;0.4</td><td align="left" colspan="1" rowspan="1">0.329</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (min&#8211;max)</td><td align="left" colspan="1" rowspan="1">4.0 (3.0&#8211;5.0)</td><td align="left" colspan="1" rowspan="1">4.0 (3.0&#8211;5.0)</td><td align="left" colspan="1" rowspan="1">4.0 (3.0&#8211;5.0)</td><td align="left" colspan="1" rowspan="1">0.362</td></tr><tr><td align="left" colspan="1" rowspan="1">Total bilirubin&#160;(mg/dL)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Mean&#8201;&#177;&#8201;SD</td><td align="left" colspan="1" rowspan="1">0.4&#8201;&#177;&#8201;0.5</td><td align="left" colspan="1" rowspan="1">0.4&#8201;&#177;&#8201;0.5</td><td align="left" colspan="1" rowspan="1">0.2&#8201;&#177;&#8201;0.3</td><td align="left" colspan="1" rowspan="1">0.071</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Median (min&#8211;max)</td><td align="left" colspan="1" rowspan="1">0 (0&#8211;0)</td><td align="left" colspan="1" rowspan="1">0 (0&#8211;3)</td><td align="left" colspan="1" rowspan="1">0 (0&#8211;1)</td><td align="left" colspan="1" rowspan="1">0.087</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SD</italic> standard deviation,<italic toggle="yes"> RNA</italic> ribonucleic acid,<italic toggle="yes"> SVR12</italic> sustained virologic response at post-treatment week 12. Percentages were calculated based on the available data</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>SVR Rates</title><p id="Par25">SVR was achieved in 95.5% (<italic toggle="yes">n</italic>&#8201;=&#8201;472) of all TN/CC HCV patients (see Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Across patient subgroups, SVR was achieved in 95.6% (<italic toggle="yes">n</italic>&#8201;=&#8201;43) of patients with HCV genotype 3, 95.7% (<italic toggle="yes">n</italic>&#8201;=&#8201;155) of patients with a recent physician visit with a diagnosis of cirrhosis, 100% (<italic toggle="yes">n&#8201;</italic> =&#8201;14) of patients with genotype 3 and a recent diagnosis of cirrhosis, 97% (<italic toggle="yes">n</italic>&#8201;=&#8201;32) of patients with HCV genotype 3 and a recent chronic HCV diagnosis, 96.9% (<italic toggle="yes">n&#8201;</italic> =&#8201;219) of patients showing signs of portal hypertension, and 93% (<italic toggle="yes">n &#8201;</italic>=&#8201;107) of patients with a recent diagnosis of illicit drug use or abuse. &#8220;Recent&#8221; was defined as within 6&#160;months prior to G/P initiation.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>SVR efficacy rate for all patients and by patient subgroup. Patients with signs of portal hypertension were those who met one of the following criteria: a prior history of a diagnosis of portal hypertension (in any time period before G/P initiation) (ICD-10 K76.6), platelet count&#8201;&lt;&#8201;100&#8201;&#215;&#8201;10<sup>9</sup>/L, albumin&#8201;&lt;&#8201;33 G/L, AST to platelet ratio index (APRI) score&#8201;&gt;&#8201;1.09.<italic toggle="yes"> AST</italic> aspartate aminotransferase,<italic toggle="yes"> G/P</italic> glecaprevir/pibrentasvir,<italic toggle="yes"> GT</italic> genotype,<italic toggle="yes"> SVR12</italic> sustained virologic response at post-treatment week 12</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40121_2023_823_Fig2_HTML.jpg"/></fig></p><p id="Par26">There was no statistically significant difference in demographics when comparing patients who achieved SVR with those who did not, including age, gender, and race/ethnicity. Of those who achieved SVR, 23% were recent illicit drug users and 38% had an extrahepatic manifestation, whereas among those who did not achieve SVR (defined as a detectable HCV RNA level), 36% had a diagnosis of illicit drug use or abuse within 6 months prior to their G/P treatment and 50% had an extrahepatic manifestation (see Table <xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par27">There was no statistically significant difference in patients&#8217; baseline laboratory values, including ALT, bilirubin, serum albumin, and RNA viral load (see Table <xref rid="Tab2" ref-type="table">2</xref>). This is likely due to the small sample size of patients who failed to achieve SVR.</p><p id="Par28">Among the 4139 patients identified as not having had a kidney or liver transplant and who had an HCV RNA test earlier than 8&#160;weeks post-treatment, 275 had an HCV RNA test post-treatment in weeks 0&#8211;4, of whom 97.5% (268/275) had undetectable HCV RNA. Of the 129 patients who had an HCV RNA test post-treatment in weeks 4&#8211;8, 98.5% (127/129) had undetectable HCV RNA.</p></sec></sec><sec id="Sec14"><title>Discussion</title><p id="Par29">This real-world study demonstrates the high effectiveness (95.5%) of 8-week G/P in TN/CC patients with HCV genotypes 1&#8211;6. These results provide further evidence of real-world data on the 8-week effectiveness of G/P in TN/CC HCV patients. This is the first study to use a large claims-linked laboratory dataset to evaluate the SVR in HCV patients with CC treated with 8-week G/P.</p><p id="Par30">The results of this study are consistent with outcomes of clinical trials [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] and early real-world evidence [<xref ref-type="bibr" rid="CR26">26</xref>]. In the EXPEDITION-8 trial, 99.7% of TN/CC patients with genotypes 1&#8211;6 achieved SVR12 in the per protocol (PP) population, and 97.7% of the corresponding patients in the intention-to-treat (ITT) population achieved SVR12 [<xref ref-type="bibr" rid="CR10">10</xref>]. When compared to baseline clinical characteristics of the EXPEDITION-8 trial, the median platelet count of patients in this study was higher (212&#8201;&#215;&#8201;10<sup>9</sup>/L versus 151&#8201;&#215;&#8201;10<sup>9</sup>/L), though the HCV RNA median viral load (6.3 log<sub>10</sub> IU/mL [2,120,000&#160;IU/mL] versus 6.3 log<sub>10</sub> IU/mL), the albumin level, and the percentage of patients considered recent illicit drug users were all similar. In the current research and in the EXPEDITION-8 trial, achievement of SVR did not depend on the patient or viral characteristics present before treatment [<xref ref-type="bibr" rid="CR10">10</xref>]. Minor differences in SVR rates between studies may be attributed to a more heterogenous real-world population, especially since clinical trials have stricter criteria for enrollment compared with real-world studies, as well as potential differences in adherence.</p><p id="Par31">In the current study, the high rate of SVR achieved was observed across patient subgroups, consistent with other G/P real-world research [<xref ref-type="bibr" rid="CR28">28</xref>]. SVR rates in patients with genotype 3 are of particular interest due to the difficulty in achieving SVR with other therapies [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Of the genotype 3 patients in our study, 95.6% achieved SVR. These results replicate outcomes from the EXPEDITION-8 trial in which the SVR12 rate was 98.4% in the PP population and 95.2% in the ITT population for patients with genotype 3 [<xref ref-type="bibr" rid="CR10">10</xref>]. In data pooled from phase 2 and 3 trials, 97% of ITT and 100% of modified ITT of genotype 3 TN patients with cirrhosis achieved SVR12 after 12&#160;weeks of G/P [<xref ref-type="bibr" rid="CR19">19</xref>]. In recent real-world research, there were only 4 TN/CC patients with genotype 3, all of whom achieved SVR12 on 8-week G/P [<xref ref-type="bibr" rid="CR26">26</xref>]; the efficacy and smaller number of patients with genotype 3 are consistent with the current study. Therefore, 8-week G/P provides an efficacious and shorter-duration treatment for patients diagnosed with the more challenging-to-treat genotype 3.</p><p id="Par32">PWID patients account for a growing number of new cases and are a target population for elimination of the disease [<xref ref-type="bibr" rid="CR9">9</xref>]. Of patients with a recent diagnosis of illicit drug use or abuse, 93% achieved SVR in this study. By comparison, in phase 2 and 3 trials for G/P, 89% of current/recent PWID patients and 98% of former/non-PWID patients achieved SVR [<xref ref-type="bibr" rid="CR13">13</xref>]. In those trials, recent/current PWID participants were more likely to be TN (94%) and had higher proportions of HCV genotype 3 infection (44%) and HIV co-infection (24%) when compared to former/non-PWID participants. PWID patients face many barriers to accessing and engaging in healthcare [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], and follow-up appointments after treatment can be a challenge to attend [<xref ref-type="bibr" rid="CR32">32</xref>]. Therefore, PWID HCV patients may benefit from a shorter HCV treatment duration.</p><p id="Par33">In the current study, 97.5% of patients had undetectable HCV RNA as early as 0&#8211;4&#160;weeks after the end of treatment. A recent clinical trial found that achieving SVR4 following 8&#160;weeks of G/P was highly predictive of long-term SVR [<xref ref-type="bibr" rid="CR33">33</xref>]. This validates the reliability of a shorter-term follow-up and can provide a shorter-duration yet effective therapy for treating and curing patients of HCV, particularly those who face barriers to accessing healthcare. In support of a shorter follow-up period, recent EASL guidelines recommend that SVR testing can be omitted for patients who are adherent and who are not high risk [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par34">This study provides real-world evidence for the recommendations outlined in the AASLD and EASL guidelines of 8-week G/P treatment in TN/CC patients [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], especially for those infected with HCV genotype 3 or who have advanced liver diseases. The added benefits of an 8-week therapy for patients with HCV, regardless of genotype and CC status, include simplified treatment and reduced costs [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par35">There are limitations on the generalizability of these findings, as this study was conducted using patients in the Symphony Health Analytic Dataset. The population described (<italic toggle="yes">n</italic>&#8201;=&#8201;494) represent&#8201;&lt;&#8201;1% of both the total population of patients&#8217; data retrieved from SHS and those that met the criteria for this study. While there were only three patients under genotype 4&#8211;6, this is consistent with US population estimates [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. The results for effectiveness represent patients with available HCV RNA data post-treatment, essentially eliminating patients lost to follow-up. In addition to this, patients were required to have a follow-up HCV RNA level at least 8&#160;weeks after the end of treatment, and so no minimum end-of-treatment follow-up was required. Therefore, the post-treatment follow-up time was not assessed. It was confirmed that the prescription for 8-week G/P was dispensed, but we cannot be certain that patients followed the prescription directions which may impact SVR rates. Due the high effectiveness rate of 8-week G/P, there were a limited number of patients available to assess patient characteristics that did not achieve SVR.</p></sec><sec id="Sec15"><title>Conclusion</title><p id="Par36">In summary, it is evident that the 8-week G/P regimen provides an efficacious and short-duration treatment in TN/CC patients of all HCV genotypes in this real-world setting. Clinical trial results, combined with the growing body of real-world evidence, can instill physicians with confidence when prescribing 8 weeks of G/P for TN/CC HCV patients. This study redefines the historical length of treatment for TN/CC HCV patients, supporting efforts to eliminate HCV as a major public health threat by 2030.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec21"><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40121_2023_823_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary file1 (PDF 187 KB)</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p>Qiujun Shao: Current employee of Novartis.</p></fn><fn><p>Hannah Brooks: Current employee of Pfizer Inc.</p></fn><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><sec id="FPar1"><title>Funding</title><p id="Par46">AbbVie sponsored the study; contributed to its design; and participated in the collection, analysis, and interpretation of the data and in the writing, reviewing, and approval of the publication.&#160;AbbVie funded&#160;the Rapid Service and Open Access of this publication.&#160;All authors had access to relevant data, and participated in the writing, review, and approval of the publication. No honoraria or payments were made for authorship.&#160;Glecaprevir was identified by AbbVie and Enanta.</p></sec><sec id="FPar2"><title>Authorship</title><p id="Par48">All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the&#160;work as a whole, and&#160;have given their approval for this version to be published.</p></sec><sec id="d32e1524"><title>Medical Writing, Editorial, and Other Assistance</title><p id="Par480">Medical writing services were provided by Natalie Mitchell, MSc, of Fishawack Facilitate, Ltd. (part of Fishawack Health, Conshohocken, PA), and funded by AbbVie. Statistical support services provided by Carlos Flores, MPH, of Genesis Research were funded by AbbVie.</p></sec><sec id="d32e1529"><title>Authorship Contributions</title><p id="Par481">Wei-Han Cheng and Steven E. Marx led the study design, Qiujun Shao led statistical analyses, and Nancy Reau and Anthony Martinez provided guidance on study design. All authors reviewed and approved the final version of the article.</p></sec><sec id="d32e1534" sec-type="COI-statement"><title>Disclosures</title><p id="Par482">Nancy Reau has received consulting fees from AbbVie, Gilead Sciences, and Abbott. Her institution has received research support from Abbott and Gilead Sciences. Qiujun Shao is a previous employee of AbbVie who is currently employed by Novartis and does not own stocks and/or stock options of the company. Hannah Brooks is a previous employee of AbbVie who is currently employed by Pfizer Inc. and may own stocks and/or stock options of the company. Anthony Martinez has received consulting fees from Gilead Sciences, AbbVie, and Intercept. He has received research support from Allergan, Intercept, Gilead Sciences, and AbbVie. He reports being a speaker for AbbVie, Gilead Sciences, Eisai, Salix, and Sirtex. Wei-Han Cheng and Steven E. Marx are employees of AbbVie and may own stocks and/or stock options of the company.</p></sec><sec id="d32e1539"><title>Compliance with Ethics Guidelines</title><p id="Par483">Data provided for the study were de-identified and Health Insurance Portability and Accountability Act (HIPAA) compliant, so review board approval was not required.</p></sec><sec id="d32e1544" sec-type="data-availability"><title>Data Availability</title><p id="Par484">The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">WHO. Hepatitis C fact sheet <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:~:text=Hepatitis%20C%20is%20a%20liver,major%20cause%20of%20liver%20cancer2020">https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:~:text=Hepatitis%20C%20is%20a%20liver,major%20cause%20of%20liver%20cancer2020</ext-link> [</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013&#8211;2016. Hepatology. 2019;69(3):1020&#8211;31.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.30297</pub-id><pub-id pub-id-type="pmcid">PMC6719781</pub-id><pub-id pub-id-type="pmid">30398671</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C cases&#8212;United States, 2009&#8211;2018. Morb Mortal Wkly Rep. 2020;69(14):399.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6914a2</pub-id><pub-id pub-id-type="pmcid">PMC7147907</pub-id><pub-id pub-id-type="pmid">32271725</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khullar</surname><given-names>V</given-names></name><name name-style="western"><surname>Firpi</surname><given-names>RJ</given-names></name></person-group><article-title>Hepatitis C cirrhosis: New perspectives for diagnosis and treatment</article-title><source>World J Hepatol</source><year>2015</year><volume>7</volume><issue>14</issue><fpage>1843</fpage><pub-id pub-id-type="doi">10.4254/wjh.v7.i14.1843</pub-id><pub-id pub-id-type="pmid">26207166</pub-id><pub-id pub-id-type="pmcid">PMC4506942</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuna</surname><given-names>L</given-names></name><name name-style="western"><surname>Jakab</surname><given-names>J</given-names></name><name name-style="western"><surname>Smolic</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>GY</given-names></name><name name-style="western"><surname>Smolic</surname><given-names>M</given-names></name></person-group><article-title>HCV extrahepatic manifestations</article-title><source>J Clin Transl Hepatol</source><year>2019</year><volume>7</volume><issue>2</issue><fpage>172</fpage><pub-id pub-id-type="pmid">31293918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14218/JCTH.2018.00049</pub-id><pub-id pub-id-type="pmcid">PMC6609844</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name><name name-style="western"><surname>Moorman</surname><given-names>AC</given-names></name><name name-style="western"><surname>Tong</surname><given-names>X</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>SC</given-names></name><name name-style="western"><surname>Rupp</surname><given-names>LB</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M</given-names></name><etal/></person-group><article-title>All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus</article-title><source>Clin Infect Dis</source><year>2016</year><volume>62</volume><issue>3</issue><fpage>289</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1093/cid/civ860</pub-id><pub-id pub-id-type="pmid">26417034</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of chronic hepatitis C: efficacy. Side effects and complications. Visc Med. 2019;35(3):161&#8211;70.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000500963</pub-id><pub-id pub-id-type="pmcid">PMC6616049</pub-id><pub-id pub-id-type="pmid">31367613</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB, Panel m. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170&#8211;218.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.08.018</pub-id><pub-id pub-id-type="pmid">32956768</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">IDSA-AASLD. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Arlington/Alexandria: Infectious Disease Society of America/American Association for the Study of Liver Diseases; 2020.</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1&#8211;6 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol. 2020;72(3):441&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2019.10.020</pub-id><pub-id pub-id-type="pmid">31682879</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reau</surname><given-names>N</given-names></name><name name-style="western"><surname>Vekeman</surname><given-names>F</given-names></name><name name-style="western"><surname>Wu</surname><given-names>E</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>YS</given-names></name></person-group><article-title>Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy</article-title><source>Hepatol Commun</source><year>2017</year><volume>1</volume><issue>5</issue><fpage>439</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1002/hep4.1049</pub-id><pub-id pub-id-type="pmid">29404471</pub-id><pub-id pub-id-type="pmcid">PMC5721412</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Flamm SL, Kort J, Marx S, Strezewski J, Bacon B, Curry MP, et al. Effectiveness of 8-week glecaprevir/pibrentasvir (G/P) for treatment na&#239;ve, non-cirrhotic patients with HCV infection in the TRIO health network. Anxiety. 2018;98(560):18.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">AbbVie Ltd. Mavyret (full prescribing information). 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.rxabbvie.com/pdf/mavyret_pi.pdf">https://www.rxabbvie.com/pdf/mavyret_pi.pdf</ext-link>. Accessed on 6 April 2021.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">AbbVie Ltd. AbbVie receives FDA approval of Mavyret&#174; (glecaprevir/pibrentasvir) to shorten treatment duration to eight weeks for treatment-na&#239;ve patients with chronic hepatitis C and compensated cirrhosis across all genotypes. 2019. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://news.Abbvie.Com/news/press-releases/abbvie-receives-fda-approval-mavyret-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-for-treatment-nave-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-across-all-genotypes.Htm">https://news.Abbvie.Com/news/press-releases/abbvie-receives-fda-approval-mavyret-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-for-treatment-nave-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-across-all-genotypes.Htm</ext-link>. Accessed on 28 June 2021.</mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">AbbVie Ltd. Maviret: product information. 2017. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/documents/product-information/maviret-epar-product-information_en.pdf">https://www.ema.europa.eu/en/documents/product-information/maviret-epar-product-information_en.pdf</ext-link>. Accessed on 17 March 2021.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">AbbVie Ltd. European Commission grants AbbVie marketing authorization shortening Maviret&#174; (glecaprevir/pibrentasvir) treatment duration to eight weeks for treatment-na&#239;ve chronic HCV patients with genotype 3 and compensated cirrhosis. 2020. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://news.Abbvie.Com/news/press-releases/european-commission-grants-abbvie-marketing-authorization-shortening-maviret-glecaprevirpibrentasvir-treatment-duration-to-eight-weeks-for-treatment-nave-chronic-hcv-patients-with-genotype-3-and-compensated-cirrhosis.Htm">https://news.Abbvie.Com/news/press-releases/european-commission-grants-abbvie-marketing-authorization-shortening-maviret-glecaprevirpibrentasvir-treatment-duration-to-eight-weeks-for-treatment-nave-chronic-hcv-patients-with-genotype-3-and-compensated-cirrhosis.Htm</ext-link>. Accessed on 28 June 2021.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D'Ambrosio</surname><given-names>R</given-names></name><name name-style="western"><surname>Pasulo</surname><given-names>L</given-names></name><name name-style="western"><surname>Puoti</surname><given-names>M</given-names></name><name name-style="western"><surname>Vinci</surname><given-names>M</given-names></name><name name-style="western"><surname>Schiavini</surname><given-names>M</given-names></name><name name-style="western"><surname>Lazzaroni</surname><given-names>S</given-names></name><etal/></person-group><article-title>Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C</article-title><source>J Hepatol</source><year>2019</year><volume>70</volume><issue>3</issue><fpage>379</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.11.011</pub-id><pub-id pub-id-type="pmid">30472321</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyles</surname><given-names>D</given-names></name><name name-style="western"><surname>Poordad</surname><given-names>F</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Alric</surname><given-names>L</given-names></name><name name-style="western"><surname>Felizarta</surname><given-names>F</given-names></name><name name-style="western"><surname>Kwo</surname><given-names>PY</given-names></name><etal/></person-group><article-title>Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><issue>2</issue><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1002/hep.29541</pub-id><pub-id pub-id-type="pmid">28926120</pub-id><pub-id pub-id-type="pmcid">PMC5817409</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, et al. Glecaprevir/pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2/3 analysis. J Viral Hepat. 2019;26(3):337&#8211;49.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvh.13038</pub-id><pub-id pub-id-type="pmcid">PMC7379735</pub-id><pub-id pub-id-type="pmid">30421537</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>GR</given-names></name><name name-style="western"><surname>Dore</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Grebely</surname><given-names>J</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>KE</given-names></name><name name-style="western"><surname>Baumgarten</surname><given-names>A</given-names></name><etal/></person-group><article-title>Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies</article-title><source>Drug Alcohol Depend</source><year>2019</year><volume>194</volume><fpage>487</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.11.007</pub-id><pub-id pub-id-type="pmid">30529905</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skeer</surname><given-names>MR</given-names></name><name name-style="western"><surname>Ladin</surname><given-names>K</given-names></name><name name-style="western"><surname>Wilkins</surname><given-names>LE</given-names></name><name name-style="western"><surname>Landy</surname><given-names>DM</given-names></name><name name-style="western"><surname>Stopka</surname><given-names>TJ</given-names></name></person-group><article-title>&#8216;Hep C&#8217;s like the common cold&#8217;: understanding barriers along the HCV care continuum among young people who inject drugs</article-title><source>Drug Alcohol Depend</source><year>2018</year><volume>190</volume><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.06.013</pub-id><pub-id pub-id-type="pmid">30071457</pub-id><pub-id pub-id-type="pmcid">PMC6367928</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Jacobson IM, Welzel T, Dylla D, Luetkemeyer A, Feld JJ, Moreno C, et al., editors. Impact of prescribed treatment duration on hepatitis C treatment adherence: comparison of 8- and 12-week treatment with glecaprevir/pibrentasvir. In: Hepatology. Hoboken: Wiley; 2019.</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Zuckerman E, Gutierrez JA, Dylla DE, de Ledinghen V, Muir AJ, Gschwantler M, et al. Eight weeks of treatment with glecaprevir/pibrentasvir is safe and efficacious in an integrated analysis of treatment-naive patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18(11):2544&#8211;53 e6.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2020.06.044</pub-id><pub-id pub-id-type="pmid">32621971</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, et al. Real-world clinical practice use of 8-week glecaprevir/pibrentasvir in treatment-naive patients with compensated cirrhosis. Adv Ther. 2020;37(9):4033&#8211;42.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-020-01449-0</pub-id><pub-id pub-id-type="pmcid">PMC7444399</pub-id><pub-id pub-id-type="pmid">32754824</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Persico M, Aglitti A, Milella M, Coppola C, Messina V, Claar E, et al. Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: the MISTRAL study. Liver Int. 2019;39(10):1852&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.14170</pub-id><pub-id pub-id-type="pmid">31175707</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, et al. Effectiveness of 8-week glecaprevir/pibrentasvir for treatment-naive, compensated cirrhotic patients with chronic hepatitis C infection. Adv Ther. 2020;37(5):2267&#8211;74.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-020-01301-5</pub-id><pub-id pub-id-type="pmcid">PMC7467488</pub-id><pub-id pub-id-type="pmid">32279176</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Zamor P, Dillon J, Dylla D, Mutimer DJ, Ghalib R, Colombo M, et al. Outcomes of patients interrupting glecaprevir/pibrentasvir treatment: a case series from clinical trials. Hepatology. 2019;70:935A-A936.</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Lampertico P, Carri&#243;n JA, Curry M, Turnes J, Cornberg M, Negro F, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112&#8211;21.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2020.01.025</pub-id><pub-id pub-id-type="pmid">32061651</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawitz</surname><given-names>E</given-names></name><name name-style="western"><surname>Mangia</surname><given-names>A</given-names></name><name name-style="western"><surname>Wyles</surname><given-names>D</given-names></name><name name-style="western"><surname>Rodriguez-Torres</surname><given-names>M</given-names></name><name name-style="western"><surname>Hassanein</surname><given-names>T</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Sofosbuvir for previously untreated chronic hepatitis C infection</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><issue>20</issue><fpage>1878</fpage><lpage>1887</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1214853</pub-id><pub-id pub-id-type="pmid">23607594</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeuzem</surname><given-names>S</given-names></name><name name-style="western"><surname>Dusheiko</surname><given-names>GM</given-names></name><name name-style="western"><surname>Salupere</surname><given-names>R</given-names></name><name name-style="western"><surname>Mangia</surname><given-names>A</given-names></name><name name-style="western"><surname>Flisiak</surname><given-names>R</given-names></name><name name-style="western"><surname>Hyland</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Sofosbuvir and ribavirin in HCV genotypes 2 and 3</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><issue>21</issue><fpage>1993</fpage><lpage>2001</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1316145</pub-id><pub-id pub-id-type="pmid">24795201</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rich</surname><given-names>ZC</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C</given-names></name><name name-style="western"><surname>Mao</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>K</given-names></name><name name-style="western"><surname>Cai</surname><given-names>W</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals</article-title><source>BMC Public Health</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1186/s12889-016-3671-z</pub-id><pub-id pub-id-type="pmid">27645935</pub-id><pub-id pub-id-type="pmcid">PMC5029046</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nouch</surname><given-names>S</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>L</given-names></name><name name-style="western"><surname>Erickson</surname><given-names>M</given-names></name><name name-style="western"><surname>Elbaharia</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.</article-title><source>Int J Drug Policy</source><year>2018</year><volume>59</volume><fpage>76</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.drugpo.2018.06.019</pub-id><pub-id pub-id-type="pmid">30048877</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="other">Gane EJ, De Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, et al., editors. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. In: The Liver Meeting Digital Experience&#8482;; 2020 Nov 13&#8211;16: virtual.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvh.13600</pub-id><pub-id pub-id-type="pmcid">PMC9292745</pub-id><pub-id pub-id-type="pmid">34448313</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emmanuel</surname><given-names>B</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>EM</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>TR</given-names></name><name name-style="western"><surname>Kottilil</surname><given-names>S</given-names></name><name name-style="western"><surname>Lau</surname><given-names>G</given-names></name></person-group><article-title>Shortening the duration of therapy for chronic hepatitis C infection</article-title><source>Lancet Gastroenterol Hepatol</source><year>2017</year><volume>2</volume><issue>11</issue><fpage>832</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(17)30053-5</pub-id><pub-id pub-id-type="pmid">28802815</pub-id><pub-id pub-id-type="pmcid">PMC5737004</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">AbbVie Inc. MappingHepC. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mappinghepc.com/">https://mappinghepc.com/</ext-link>. Accessed on 3 Oct 2022.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Reau N, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, et al. Epidemiology and clinical characteristics of individuals with hepatitis C virus infection in the United States, 2017&#8211;2019. Adv Ther. 2021;38(12):5777&#8211;90.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-021-01928-y</pub-id><pub-id pub-id-type="pmcid">PMC8548268</pub-id><pub-id pub-id-type="pmid">34704194</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>